Type 2 diabetes patients who took insulin degludec showed lower rates of overall hypoglycemic episodes per year than their counterparts who received insulin glargine, according to two Phase III studies in The Lancet. Researchers also found that patients with type 1 or type 2 diabetes who were on degludec treatment had a 25% reduction in nocturnal hypoglycemia rates compared with those who took glargine.

Full Story:
Medical News Today

Related Summaries